Nomenclature of HBV core protein-targeting antivirals

Fabien Zoulim; Adam Zlotnick; Stephanie Buchholz; Eric Donaldson; John Fry; Anuj Gaggar; Jianming Hu; Michael Kann; Oliver Lenz; Kai Lin; Nagraj Mani; Michael Nassal; William Delaney; Su Wang; Gabriel Westman; Veronica Miller; Harry L.A. Janssen

doi:10.1038/s41575-022-00700-z

Nomenclature of HBV core protein-targeting antivirals

Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William Delaney, Su Wang, Gabriel Westman, Veronica Miller, Harry L.A. Janssen

Research output: Contribution to journal › Comment/debate › peer-review

36 Scopus citations

Original language	English (US)
Pages (from-to)	748-750
Number of pages	3
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	19
Issue number	12
DOIs	https://doi.org/10.1038/s41575-022-00700-z
State	Published - Dec 2022

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

Access to Document

10.1038/s41575-022-00700-z

Cite this

Zoulim, F., Zlotnick, A., Buchholz, S., Donaldson, E., Fry, J., Gaggar, A., Hu, J., Kann, M., Lenz, O., Lin, K., Mani, N., Nassal, M., Delaney, W., Wang, S., Westman, G., Miller, V., & Janssen, H. L. A. (2022). Nomenclature of HBV core protein-targeting antivirals. Nature Reviews Gastroenterology and Hepatology, 19(12), 748-750. https://doi.org/10.1038/s41575-022-00700-z

@article{21d5914ee7b243ffac40c0051e802179,

title = "Nomenclature of HBV core protein-targeting antivirals",

author = "Fabien Zoulim and Adam Zlotnick and Stephanie Buchholz and Eric Donaldson and John Fry and Anuj Gaggar and Jianming Hu and Michael Kann and Oliver Lenz and Kai Lin and Nagraj Mani and Michael Nassal and William Delaney and Su Wang and Gabriel Westman and Veronica Miller and Janssen, {Harry L.A.}",

note = "Funding Information: F.Z. has received grants from Assembly Biosciences, Beam, Janssen and Viravaxx and is also a consultant for Assembly, Aligos, Antios, Arbutus, Gilead Sciences, GlaxoSmithKline, Janssen and Vir Biotechnology. A.Z. has equity in Assembly Biosciences and serves on their scientific advisory board. A.Z. is also a founder and Chief Scientific Officer of Door Pharmaceutical. J.F. is an employee of Aligos Therapeutics. A.G. is a former employee and current stakeholder of Gilead Sciences. J.H. has been supported by funding from the National Institute of Allergy and Infectious Disease/NIH and Gilead for work relevant here and has consulted for Arbutus, Bristol Myers Squibb, Gilead, Janssen, Roche and Sanofi. O.L. is an employee of Janssen and is a shareholder of Johnson & Johnson. N.M. is an employee of Arbutus Biopharma. W.D. is an employee at Assembly Biosciences and owns stock in Assembly Biosciences and Gilead. S.W. has received funding from Gilead. V.M. receives grant funding for the HBV Forum from Abbott, Aligos Therapeutis, Altimmune, Antios Therapeutics, Assembly Biosciences, Enanta Pharma, Enyo Pharma, Gilead, GlaxoSmithKline, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology and Virion. H.L.A.J. has received grants from AbbVie, Gilead, GlaxoSmithKline, Janssen, Roche and Vir Biotechnology, and is also a consultant for Aligos, Antios, Arbutus, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, VBI Vaccines, Vir Biotechnology and Viroclinics. S.B., E.D., M.K., K.L., M.N. and G.W. declare no competing interests. ",

year = "2022",

month = dec,

doi = "10.1038/s41575-022-00700-z",

language = "English (US)",

volume = "19",

pages = "748--750",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - Nomenclature of HBV core protein-targeting antivirals

AU - Zoulim, Fabien

AU - Zlotnick, Adam

AU - Buchholz, Stephanie

AU - Donaldson, Eric

AU - Fry, John

AU - Gaggar, Anuj

AU - Hu, Jianming

AU - Kann, Michael

AU - Lenz, Oliver

AU - Lin, Kai

AU - Mani, Nagraj

AU - Nassal, Michael

AU - Delaney, William

AU - Wang, Su

AU - Westman, Gabriel

AU - Miller, Veronica

AU - Janssen, Harry L.A.

N1 - Funding Information: F.Z. has received grants from Assembly Biosciences, Beam, Janssen and Viravaxx and is also a consultant for Assembly, Aligos, Antios, Arbutus, Gilead Sciences, GlaxoSmithKline, Janssen and Vir Biotechnology. A.Z. has equity in Assembly Biosciences and serves on their scientific advisory board. A.Z. is also a founder and Chief Scientific Officer of Door Pharmaceutical. J.F. is an employee of Aligos Therapeutics. A.G. is a former employee and current stakeholder of Gilead Sciences. J.H. has been supported by funding from the National Institute of Allergy and Infectious Disease/NIH and Gilead for work relevant here and has consulted for Arbutus, Bristol Myers Squibb, Gilead, Janssen, Roche and Sanofi. O.L. is an employee of Janssen and is a shareholder of Johnson & Johnson. N.M. is an employee of Arbutus Biopharma. W.D. is an employee at Assembly Biosciences and owns stock in Assembly Biosciences and Gilead. S.W. has received funding from Gilead. V.M. receives grant funding for the HBV Forum from Abbott, Aligos Therapeutis, Altimmune, Antios Therapeutics, Assembly Biosciences, Enanta Pharma, Enyo Pharma, Gilead, GlaxoSmithKline, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology and Virion. H.L.A.J. has received grants from AbbVie, Gilead, GlaxoSmithKline, Janssen, Roche and Vir Biotechnology, and is also a consultant for Aligos, Antios, Arbutus, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, VBI Vaccines, Vir Biotechnology and Viroclinics. S.B., E.D., M.K., K.L., M.N. and G.W. declare no competing interests.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85139459870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139459870&partnerID=8YFLogxK

U2 - 10.1038/s41575-022-00700-z

DO - 10.1038/s41575-022-00700-z

M3 - Comment/debate

C2 - 36207612

AN - SCOPUS:85139459870

SN - 1759-5045

VL - 19

SP - 748

EP - 750

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

IS - 12

ER -

Nomenclature of HBV core protein-targeting antivirals

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this